PDGF-AA (Human) recombinant proteins
- Known as:
- PDGF-AA (Human) Rec. proteins
- Catalog number:
- rAP-0036-10
- Product Quantity:
- 10.00 ug
- Category:
- -
- Supplier:
- AngoiPro
- Gene target:
- PDGF- (Human) recombinant proteins
Related genes to: PDGF-AA (Human) recombinant proteins
- Gene:
- PDGFA NIH gene
- Name:
- platelet derived growth factor subunit A
- Previous symbol:
- -
- Synonyms:
- PDGF1, PDGF-A
- Chromosome:
- 7p22.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2016-10-05
- Gene:
- PDGFRA NIH gene
- Name:
- platelet derived growth factor receptor alpha
- Previous symbol:
- -
- Synonyms:
- CD140a, PDGFR2, GAS9
- Chromosome:
- 4q12
- Locus Type:
- gene with protein product
- Date approved:
- 1989-05-19
- Date modifiied:
- 2019-04-23
- Gene:
- PDGFRB NIH gene
- Name:
- platelet derived growth factor receptor beta
- Previous symbol:
- PDGFR
- Synonyms:
- JTK12, CD140b, PDGFR1
- Chromosome:
- 5q32
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-10-05
Related products to: PDGF-AA (Human) recombinant proteins
Related articles to: PDGF-AA (Human) recombinant proteins
- Fetal growth restriction (FGR) is a complex condition with highly heterogeneous clinical outcomes, making prenatal distinction between transient and persistent growth failure challenging. This study aims to identify amniotic fluid (AF) biomarkers capable of differentiating distinct FGR trajectories and characterizing persistent growth failure mechanisms. - Source: PubMed
Publication date: 2026/08/15
Cao YanHao WenjingWang YanChai ChongchongLi YouranLiu YingZhu HongyuanLu YifanWang DongZhai YanhongYan YoushengCao Zheng - Drug resistance hinders treatment success in many cancers. Sunitinib is one of the first-line treatments in renal cell carcinoma (RCC), but resistance develops during treatment. By ameliorating their angiogenic ability, tumor cells finding a different route of escape in RCC is a majorconcern. We aimed to investigate the effects of the succinic acid sunitinib combination on the angiogenesis mechanism in sunitinib-resistant renal cancer cell lines. Gene expression levels of VEGF-A, VEGF-C, PDGF-A, HIF1A, TGF-β, VHL, ANGPT1, and TIE2; protein levels of VEGF-A, HIF1A, and VHL were compared before, and after succinic acid-sunitinib combination treatment in ACHN cells that developed sunitinib resistance. In the sunitinib-resistant group, HIF1A, TGF-β, ANGPT1, and TIE2 gene expression levels were significantly decreased with a combination therapy of succinic acid at 25 µMcompared to the resistant control group. Our study focused on clarifying the increase of angiogenic factors in sunitinib-resistant RCC cells following sunitinib treatment and the subsequent changes in the combination of succinic acid as a secondary treatment agent. It is also anticipated to guide future studies exploring the potential clinical application of the combination of sunitinib and succinic acid. - Source: PubMed
Publication date: 2026/08/12
Ertugrul BarisKavsara Goksu KasarciBireller SinemErgen ArzuCakmakoglu Bedia - Platelet-derived growth factors (PDGFs) and their cognate receptors (PDGFRα/β) play critical roles in breast cancer progression and metastasis. This review summarizes current evidence of PDGF ligand and receptor expression patterns, oncogenic functions, prognostic significance and therapeutic targetability, with a specific focus on small molecule inhibition. PDGF-PDGFR signaling is known to contribute to epithelial to mesenchymal transition, cancer stem cell maintenance, desmoplasia, angiogenesis, and immune modulation. Additionally, the four PDGF ligands have distinct oncogenic functions. PDGFA and PDGFB have been implicated in breast cancer associated brain metastasis, while PDGFC has been shown to play a crucial role in fibroblast activation. PDGFD, while less studied, may activate epithelial to mesenchymal transition in breast cancer. High expression of PDGFA, PDGFB, PDGFC, and stromal PDGFRβ correlate with poor patient survival, highlighting their potential as candidate biomarkers. We specifically focus on evaluating current therapeutic strategies which target the PDGF-PDGFR axis, including neutralizing antibodies, aptamers, and small molecule inhibitors, which show preclinical promise but limited clinical success in breast cancer to date. We discuss future research directions with emphasis on identifying selective inhibitors, utilizing PDGF-PDGFR signaling components for patient stratification, and combination with immunotherapies. - Source: PubMed
Publication date: 2026/08/07
Reardon Jesse JMossing Alexis APackard Rebecca LShah SajitaSizemore Gina M - Ovarian endometrioma (OEM) is a common manifestation of endometriosis and is associated with both local lesions and systemic alterations. While immune dysregulation and metabolic disturbances have been individually reported in endometriosis, whether these changes are coordinated at the circulating molecular level in OEM remains unclear. - Source: PubMed
Publication date: 2026/07/22
Chen NaHu YubingXiao TianxiaMa YunZhu LitongGao JiahongZhang Jian VJin Ping - Cirrhosis is the end-stage of chronic liver disease characterized by progressive hepatic fibrosis and persistent immune dysregulation, yet the mechanisms by which immune cell crosstalk drives disease progression remain poorly understood. - Source: PubMed
Publication date: 2026/07/20
Chen BochenLi RuolingZhang ShuyaLou YitingZhang ShuoLou JiahengZhang JingchengXu ChuyunJiang TaoLv Yuanlin